Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Motesanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 18/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 2/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Motesanib SCHEMBL187470 | 1.00 | KDR (1.00) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL445079 | 0.99 | KDR (0.98) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL29353301 | 0.97 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL446673 | 0.97 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL29361754 | 0.97 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3150119 | 0.92 | KDR (0.85) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL4537062 | 0.89 | KDR (0.81) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3144781 | 0.89 | KDR (0.81) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL444347 | 0.88 | KDR (0.79) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3155345 | 0.88 | KDR (0.79) | KDRRETMAP3K20RIPK3CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3621 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005552-A | Medicine for improving expression of lysosomal related transmembrane protein 4B and screening method thereof | 安徽医科大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4719387-A2 | COMPLEMENT ANTIBODY-DRUG CONJUGATES | ADS Therapeutics LLC (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260048156-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2026-02-19 | — | — | US | claimed |
| US-20260021106-A1 | COMBINATION THERAPY FOR TREATING CANCERS | GEISTLICH PHARMA AG (CH) | 2026-01-22 | — | — | US | claimed |
| EP-3738580-B1 | OPHTHALMOLOGICAL IMPLANT FOR USE IN THE TREATMENT OF AN OCULAR DISEASE AND IMPLANTATION TOOL COMPRISING SUCH AN OPHTHALMOLOGIC IMPLANT | ZEISS CARL MEDITEC AG (DE) | 2026-01-14 | — | — | EP | claimed |
| EP-4673152-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | Kenai Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| WO-2022061251-A1 | COMPOUNDS AND METHODS FOR KRAS MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2022-03-24 | — | — | WO | claimed |
| WO-2022020648-A9 | INHIBITORS OF THE ARTEMIN PATHWAY FOR TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2022-03-10 | — | — | WO | claimed |
| EP-3572420-B1 | PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECH CO LTD (CN) | 2022-03-09 | — | — | EP | claimed |
| CN-107949354-B | Coated punctal plugs | 因赛普特有限责任公司 | 2022-02-18 | — | — | CN | claimed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3953390-A1 | HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| US-11246864-B2 | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | ADS THERAPEUTICS LLC (US) | 2022-02-15 | — | — | US | claimed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022026510-A1 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | SEAGEN INC. (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022020648-A1 | INHIBITORS OF THE ARTEMIN PATHWAY FOR TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2022-01-27 | — | — | WO | claimed |